
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8228336/publications.pdf Version: 2024-02-01



LULIO ROBES

#	Article	IF	CITATIONS
1	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. Psychological Medicine, 2023, 53, 3396-3405.	4.5	9
2	The impact of school-based screening on service use in adolescents at risk for mental health problems and risk-behaviour. European Child and Adolescent Psychiatry, 2023, 32, 1745-1754.	4.7	3
3	A replication study of JTC bias, genetic liability for psychosis and delusional ideation. Psychological Medicine, 2022, 52, 1777-1783.	4.5	10
4	Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway. Psychological Medicine, 2022, 52, 1910-1922.	4.5	14
5	Migration history and risk of psychosis: results from the multinational EU-GEI study. Psychological Medicine, 2022, 52, 2972-2984.	4.5	22
6	Early Impact of the COVID-19 Outbreak on Sleep in a Large Spanish Sample. Behavioral Sleep Medicine, 2022, 20, 100-115.	2.1	15
7	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country caseâ^'control study. Psychological Medicine, 2022, 52, 3668-3676.	4.5	7
8	Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study. CNS Spectrums, 2022, 27, 716-723.	1.2	3
9	Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2022, 113, 110440.	4.8	10
10	Results of the COVID-19 mental health international for the general population (COMET-G) study. European Neuropsychopharmacology, 2022, 54, 21-40.	0.7	84
11	A polygenic approach to the association between smoking and schizophrenia. Addiction Biology, 2022, 27, e13104.	2.6	6
12	Polygenic contribution to the relationship of loneliness and social isolation with schizophrenia. Nature Communications, 2022, 13, 51.	12.8	16
13	Childhood Maltreatment, Educational Attainment, and IQ: Findings From a Multicentric Case-control Study of First-episode Psychosis (EU-GEI). Schizophrenia Bulletin, 2022, 48, 575-589.	4.3	9
14	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case–Control Study. Schizophrenia Bulletin, 2022, 48, 1104-1114.	4.3	9
15	Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2022, 15, 22-28.	0.3	1
16	Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2022, 15, 14-21.	0.3	2
17	Suicidal Ideation Trends and Associated Factors in Different Large Spanish Samples During the First Year of the COVID-19 Pandemic. Journal of Clinical Psychiatry, 2022, 83, .	2.2	3
18	Does COVID-19 psychological fatigue exist? Results of three online cross-sectional studies conducted in Spain from April 2020 to March 2021. Journal of Global Health, 2022, 12, 05001.	2.7	7

JULIO BOBES

#	Article	IF	CITATIONS
19	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
20	Is it possible to stage schizophrenia? A systematic review. Translational Psychiatry, 2022, 12, 197.	4.8	3
21	Utility and validity of the Brief Psychiatric Rating Scale (BPRS) as a transdiagnostic scale. Psychiatry Research, 2022, 314, 114659.	3.3	12
22	Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMiSE trial. European Psychiatry, 2022, 65, .	0.2	4
23	The effect of different degrees of lockdown and self-identified gender on anxiety, depression and suicidality during the COVID-19 pandemic: Data from the international COMET-G study Psychiatry Research, 2022, 315, 114702.	3.3	17
24	Are older adults also at higher psychological risk from COVID-19?. Aging and Mental Health, 2021, 25, 1297-1304.	2.8	78
25	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study. Psychological Medicine, 2021, 51, 1329-1337.	4.5	38
26	Social disadvantage, linguistic distance, ethnic minority status and first-episode psychosis: results from the EU-GEI case–control study. Psychological Medicine, 2021, 51, 1536-1548.	4.5	58
27	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. Psychological Medicine, 2021, 51, 623-633.	4.5	34
28	Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study. CNS Spectrums, 2021, 26, 290-298.	1.2	5
29	Network structure of psychoticâ€like experiences in adolescents: Links with risk and protective factors. Microbial Biotechnology, 2021, 15, 595-605.	1.7	13
30	Difficulties in delivery and depressive symptomatology in schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 66-68.	0.3	2
31	Consumo de alcohol y factores de riesgo de conductas autolesivas en adolescentes españoles. Revista De Psicologia De La Salud, 2021, 33, 53.	0.5	4
32	Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: Results from the EUGEI study. European Psychiatry, 2021, 64, e25.	0.2	18
33	Dificultades en el parto y sintomatologÃa depresiva en la esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 66-68.	1.8	5
34	La formación del residente de PsiquiatrÃa: Resumen de la Mesa de Debate realizada durante el XXII Congreso Nacional de PsiquiatrÃa. España, 2019. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 74-76.	1.8	0
35	The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study. Schizophrenia Bulletin, 2021, 47, 1674-1684.	4.3	17
36	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. Schizophrenia Bulletin, 2021, 47, 1653-1662.	4.3	4

#	Article	IF	CITATIONS
37	Psychopathological Symptom Load and Distinguishable Cerebral Blood Flow Velocity Patterns in Patients With Schizophrenia and Healthy Controls: A Functional Transcranial Doppler Study. Frontiers in Psychiatry, 2021, 12, 679021.	2.6	6
38	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 164-176.	0.3	3
39	The prevention of relapses in first episodes of schizophrenia: The 2EPs Project, background, rationale and study design. Revista De PsiquiatrÃa Y Salud Mental, 2021, 14, 164-176.	1.8	13
40	Estrategias de intervención en la prevención de comportamiento suicida en pacientes con trastorno por consumo de sustancias en tiempos de COVID-19. Revista De Psicologia De La Salud, 2021, 33, 185.	0.5	1
41	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. Translational Psychiatry, 2021, 11, 423.	4.8	12
42	Real-World Functioning in Patients With Schizophrenia: Beyond Negative and Cognitive Symptoms. Frontiers in Psychiatry, 2021, 12, 700747.	2.6	8
43	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. Schizophrenia Research, 2021, 236, 69-79.	2.0	4
44	Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. Schizophrenia Research, 2021, 236, 19-28.	2.0	5
45	Factors associated with alcohol and tobacco consumption as a coping strategy to deal with the coronavirus disease (COVID-19) pandemic and lockdown in Spain. Addictive Behaviors, 2021, 121, 107003.	3.0	23
46	Excessive and pathological Internet use – Risk-behavior or psychopathology?. Addictive Behaviors, 2021, 123, 107045.	3.0	20
47	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
48	Chronic obstructive pulmonary disease in severe mental illness: A timely diagnosis to advance the process of quitting smoking. European Psychiatry, 2021, 64, e22.	0.2	8
49	Spanish validation of the Empirically Developed Clinical Staging Model (EmDe-5) for patients with bipolar disorder. Revista De PsiquiatrÃa Y Salud Mental, 2021, , .	1.8	0
50	Functional transcranial Doppler: Selection of methods for statistical analysis and representation of changes in flow velocity. Health Science Reports, 2021, 4, e400.	1.5	2
51	Funcionamiento cognitivo en pacientes con trastorno por uso de alcohol que inician tratamiento ambulatorio de deshabituación alcohólica. Revista De Psicologia De La Salud, 2021, 33, 161.	0.5	2
52	Estudio para la determinación de medidas de resultados en salud relevantes en el trastorno por consumo de opiáceos. Análisis de Decisión Multicriterio. Revista De Psicologia De La Salud, 2021, 33, 109.	0.5	0
53	Exploring the factor structure of the mini-ICF-APP in an inpatient clinical sample, according to the psychiatric diagnosis. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2021, 14, 186-195.	0.3	0
54	The mediating role of impulsivity in the relationship between suicidal behaviour and early traumatic experiences in depressed subjects. European Psychiatry, 2021, 64, S583-S583.	0.2	0

#	Article	IF	CITATIONS
55	Insomnia associated with neutrophil/lymphocyte ratio in female patients with schizophrenia. European Psychiatry, 2021, 64, S806-S806.	0.2	1
56	Association of traumatic events in childhood, impulsivity and decision-making with previous suicide attempt and/or current suicidal ideation in adult patients with major depressive disorder. European Psychiatry, 2021, 64, S177-S178.	0.2	0
57	COVID-19 psychological impact in patients with depressive disorder: Differences based on their age. European Psychiatry, 2021, 64, S674-S675.	0.2	0
58	Factors associated with real-world functioning in first stages of schizophrenia disorder. European Psychiatry, 2021, 64, S805-S805.	0.2	0
59	P.0564 Active suicidal ideation one year after the beginning of COVID-19 pandemic in a large spanish sample: risk and protective factors. European Neuropsychopharmacology, 2021, 53, S414-S415.	0.7	0
60	P.0787 Women with schizophrenia have better communication capacity than men, but surprisingly, alogia plays no role on it. European Neuropsychopharmacology, 2021, 53, S575.	0.7	0
61	P.0786 Cognitive and depressive symptoms lose their impact on real world functioning in the later stages of schizophrenia in both genders. European Neuropsychopharmacology, 2021, 53, S574.	0.7	0
62	P.0647 Psychological impact in patients with common mental disorders after six months of COVID-19 outbreak. European Neuropsychopharmacology, 2021, 53, S476-S477.	0.7	0
63	P.0397 Orexin a in patients with bipolar disorder treated with lithium. European Neuropsychopharmacology, 2021, 53, S285-S286.	0.7	0
64	P.0776 Premorbid childhood and adolescent functioning trajectories in patients with first-episode of schizophrenia using Latent Class Growth Analysis: 2-year follow-up study. European Neuropsychopharmacology, 2021, 53, S566.	0.7	0
65	Spanish Validation of the MAP-SR: Two Heads Better Than One for the Assessment of Negative Symptoms of Schizophrenia. Psicothema, 2021, 33, 473-480.	0.9	0
66	Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene–environment interaction. The EUGEI study. Psychological Medicine, 2020, 50, 1884-1897.	4.5	28
67	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. Schizophrenia Bulletin, 2020, 46, 517-529.	4.3	14
68	Life Events Predicting the First Onset of Adolescent Direct Self-Injurious Behavior—A Prospective Multicenter Study. Journal of Adolescent Health, 2020, 66, 195-201.	2.5	31
69	Influence of social cognition as a mediator between cognitive reserve and psychosocial functioning in patients with first episode psychosis. Psychological Medicine, 2020, 50, 2702-2710.	4.5	31
70	Personalized medicine begins with the phenotype: identifying antipsychotic response phenotypes in a firstâ€episode psychosis cohort. Acta Psychiatrica Scandinavica, 2020, 141, 541-552.	4.5	6
71	Relevant risk factors of repeated suicidal attempts in a sample of outpatients. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2020, 13, 11-21.	0.3	2
72	Early Psychological Correlates Associated With COVID-19 in A Spanish Older Adult Sample. American Journal of Geriatric Psychiatry, 2020, 28, 1287-1298.	1.2	30

#	Article	IF	CITATIONS
73	A Smart Band for Automatic Supervision of Restrained Patients in a Hospital Environment. Sensors, 2020, 20, 5211.	3.8	4
74	Hostility and aggressive behaviour in first episode psychosis: Results from the OPTiMiSE trial. Schizophrenia Research, 2020, 223, 271-278.	2.0	9
75	P.247 Psychological impact of COVID-19 confinement among people with history of mental disorders (bipolar, anxiety, depression) and general population in Spain. European Neuropsychopharmacology, 2020, 40, S141-S142.	0.7	0
76	P.502 Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis. European Neuropsychopharmacology, 2020, 40, S281-S282.	0.7	0
77	P.690 Post-traumatic stress symptoms during the COVID-19 in different regions of Spain. European Neuropsychopharmacology, 2020, 40, S393-S394.	0.7	0
78	The Mediating Role of Impulsivity in the Relationship Between Suicidal Behavior and Early Traumatic Experiences in Depressed Subjects. Frontiers in Psychiatry, 2020, 11, 538172.	2.6	7
79	Suicide. The post-COVID era: A time for action. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2020, 13, 229-231.	0.3	0
80	The King's neurologist. Lancet Neurology, The, 2020, 19, 977.	10.2	0
81	Suicide. The post-COVID era: A time for action. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 229-231.	1.8	1
82	The Suicide Prevention and Intervention Study (SURVIVE): Study protocol for a multisite cohort study with nested randomized-controlled trials. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.8	1
83	Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum. Epidemiology and Psychiatric Sciences, 2020, 29, e182.	3.9	36
84	COVID-19 lockdown in people with severe mental disorders in Spain: Do they have a specific psychological reaction compared with other mental disorders and healthy controls?. Schizophrenia Research, 2020, 223, 192-198.	2.0	64
85	Smoking cessation improves clinical outcome in severe mental disorders and is modulated by genetic variability at CHRNA5 gene. Schizophrenia Research, 2020, 222, 516-519.	2.0	0
86	Early psychological impact of the 2019 coronavirus disease (COVID-19) pandemic and lockdown in a large Spanish sample. Journal of Global Health, 2020, 10, 020505.	2.7	57
87	Cognitive impairment and C-reactive protein in clinically stable schizophrenia outpatients: a focus on sex differences. Scientific Reports, 2020, 10, 15963.	3.3	5
88	Compulsory admissions of patients with mental disorders: State of the art on ethical and legislative aspects in 40 European countries. European Psychiatry, 2020, 63, e82.	0.2	23
89	Assessing the severity of psychiatric disorders using the Health of the Nation Outcome Scales: An equipercentile linking analysis. Australian and New Zealand Journal of Psychiatry, 2020, 54, 1192-1199.	2.3	1
90	Real-Time Assessment of Stress and Stress Response Using Digital Phenotyping: A Study Protocol. Frontiers in Digital Health, 2020, 2, 544418.	2.8	2

JULIO BOBES

#	Article	IF	CITATIONS
91	Despedida como Editor de la RPSM. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 51-52.	1.8	0
92	Sex-dependent grades of haematopoietic modulation in patients with major depressive episodes are associated with suicide attempts. European Neuropsychopharmacology, 2020, 40, 17-30.	0.7	10
93	Psychiatry residency during the COVID-19 pandemic: Navigating uncharted waters. Asian Journal of Psychiatry, 2020, 53, 102214.	2.0	2
94	Influence of coping strategies on the efficacy of YAM (Youth Aware of Mental Health): a universal school-based suicide preventive program. European Child and Adolescent Psychiatry, 2020, 29, 1671-1681.	4.7	17
95	Association of cannabinoid receptor genes (CNR1 and CNR2) polymorphisms and panic disorder. Anxiety, Stress and Coping, 2020, 33, 256-265.	2.9	9
96	Neutrophil-to-lymphocyte ratio: A potential new peripheral biomarker of suicidal behavior. European Psychiatry, 2020, 63, e14.	0.2	51
97	Association study of candidate genes with obesity and metabolic traits in antipsychotic-treated patients with first-episode psychosis over a 2-year period. Journal of Psychopharmacology, 2020, 34, 514-523.	4.0	12
98	Longitudinal effects of clozapine concentration and clozapine to N-desmethylclozapine ratio on cognition: A mediation model. European Neuropsychopharmacology, 2020, 33, 158-163.	0.7	9
99	The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme. Social Psychiatry and Psychiatric Epidemiology, 2020, 55, 645-657.	3.1	41
100	Factores predictores de riesgo de repetición de intento de suicidio en una muestra de pacientes ambulatorios. Revista De PsiquiatrÃa Y Salud Mental, 2020, 13, 11-21.	1.8	10
101	Birth weight and antipsychotic induced weight gain: A prenatal programming approach in the PEPs study. Schizophrenia Research, 2020, 218, 292-294.	2.0	6
102	Doing Nothing is Sometimes Worse: Comparing Avoidant versus Approach Coping Strategies with Peer Victimization and Their Association to Depression and Suicide Ideation. Journal of School Violence, 2020, 19, 456-469.	1.9	14
103	Twelve-month service use, suicidality and mental health problems of European adolescents after a school-based screening for current suicidality. European Child and Adolescent Psychiatry, 2020, , 1.	4.7	7
104	Detección de ansiedad y depresión en Atención Primaria: utilidad de 2 escalas breves adaptadas a los nuevos criterios CIE-11-AP. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.8	2
105	Exploring the factor structure of the mini-ICF-APP in an inpatient clinical sample, according to the psychiatric diagnosis. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.8	5
106	¿Se observarán cambios en el consumo de alcohol y tabaco durante el confinamiento por COVID-19?. Revista De Psicologia De La Salud, 2020, 32, 85.	0.5	65
107	Prevalence of Passive Suicidal Ideation in the Early Stage of the Coronavirus Disease 2019 (COVID-19) Pandemic and Lockdown in a Large Spanish Sample. Journal of Clinical Psychiatry, 2020, 81, .	2.2	16
108	Validation of a European Spanish-version of the Self-Evaluation of Negative Symptoms (SNS) in patients with schizophrenia. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.8	2

JULIO BOBES

#	Article	IF	CITATIONS
109	Validation of a European Spanish adaptation of the Apathy Evaluation Scale-self-rated version (AES-S) in patients with schizophrenia. Revista De PsiquiatrÃa Y Salud Mental, 2020, , .	1.8	2
110	Dimensional analysis of depressive, anxious and somatic symptoms presented by primary care patients and their relationship with ICD-11 PHC proposed diagnoses. Psychological Medicine, 2019, 49, 764-771.	4.5	13
111	Biâ€directional longitudinal associations between different types of bullying victimization, suicide ideation/attempts, and depression among a large sample of European adolescents. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2019, 60, 209-215.	5.2	106
112	Patient characteristics driving clinical utility in psychiatric pharmacogenetics: a reanalysis from the AB-GEN multicentric trial. Journal of Neural Transmission, 2019, 126, 95-99.	2.8	4
113	Phenotypic factors associated with amisulprideâ€induced weight gain in firstâ€episode psychosis patients (from the OPT iMi SE cohort). Acta Psychiatrica Scandinavica, 2019, 140, 283-290.	4.5	6
114	Clinical staging in severe mental disorders: Bipolar disorder, depression and schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 106-115.	0.3	7
115	"Readiness to Change―Predicts Efficacy of Reduction among Smokers with Severe Mental Illness. European Addiction Research, 2019, 25, 256-262.	2.4	3
116	Pharmacological treatment of obsessive compulsive disorder in adults: A clinical practice guideline based on the ADAPTE methodology. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 77-91.	0.3	3
117	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. Journal of Clinical Medicine, 2019, 8, 1081.	2.4	10
118	Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study. Schizophrenia Bulletin, 2019, 45, 960-965.	4.3	46
119	A longitudinal examination of the interpersonal theory of suicide and effects of schoolâ€based suicide prevention interventions in a multinational study of adolescents. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2019, 60, 1104-1111.	5.2	31
120	Predicting real-world functioning in outpatients with schizophrenia: Role of inflammation and psychopathology. Psychiatry Research, 2019, 280, 112509.	3.3	19
121	White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?. Frontiers in Psychiatry, 2019, 10, 676.	2.6	5
122	Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study. International Journal of Neuropsychopharmacology, 2019, 22, 681-697.	2.1	28
123	Association of childhood trauma and genetic variability of CRH-BP and FKBP5 genes with suicidal behavior in bipolar patients. Journal of Affective Disorders, 2019, 255, 15-22.	4.1	20
124	Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study. World Psychiatry, 2019, 18, 173-182.	10.4	127
125	Can interleukin-2 and interleukin-1β be specific biomarkers of negative symptoms in schizophrenia?. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 9-16.	0.3	0
126	History of Lifetime Cannabis Use Is Associated with Better Cognition and Worse Real-World Functioning in Schizophrenia Spectrum Disorders. European Addiction Research, 2019, 25, 111-118.	2.4	7

#	Article	IF	CITATIONS
127	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. Lancet Psychiatry,the, 2019, 6, 427-436.	7.4	528
128	CIBERSAM: Ten years of collaborative translational research in mental disorders. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2019, 12, 1-8.	0.3	5
129	Emotion recognition in major depressed patients: Evidence of lack of relationship with suicidal behavior. European Neuropsychopharmacology, 2019, 29, S376-S377.	0.7	0
130	Los cambios estructurales de la retina, ¿nuevos biomarcadores de los trastornos mentales? Una revisión sistemática y sÃntesis temática de la literatura. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 116-129.	1.8	9
131	Spanish validation of the Barcelona TEMPS-A questionnaire in patients with bipolar disorder and general population. Journal of Affective Disorders, 2019, 249, 199-207.	4.1	11
132	Assessing the severity of functional impairment of psychiatric disorders: equipercentile linking the mini-ICF-APP and CGI. Health and Quality of Life Outcomes, 2019, 17, 174.	2.4	10
133	P.378 Metabolic syndrome and quality of life in schizophrenia and bipolar disorder. European Neuropsychopharmacology, 2019, 29, S268-S269.	0.7	0
134	P.586 Comorbid depression in patients with schizophrenia: does it have an impact on their neurocognitive functioning?. European Neuropsychopharmacology, 2019, 29, S407-S408.	0.7	0
135	Estadificación clÃnica en los trastornos mentales graves: trastorno bipolar, depresión y esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 106-115.	1.8	15
136	Barreras para la recuperación completa en la depresión mayor: estudio transversal multicéntrico en la práctica clÃnica. Estudio RECORD. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 141-150.	1.8	0
137	Smoking Status and Cost of Illness in Patients with Depressive Disorder Based on the National Health Survey in Spain. Substance Use and Misuse, 2019, 54, 713-723.	1.4	2
138	Updated European Consensus Statement on diagnosis and treatment of adult ADHD. European Psychiatry, 2019, 56, 14-34.	0.2	330
139	Diez años de investigación traslacional colaborativa en enfermedades mentales: el CIBERSAM. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 1-8.	1.8	68
140	Latent profile analysis of psychosis liability in a communityâ€derived sample of adolescents: Links with mental health difficulties, suicidal ideation, bipolarâ€like experiences and psychoticâ€like experiences. Microbial Biotechnology, 2019, 13, 1111-1120.	1.7	10
141	Influence of secondary sources in the Brief Negative Symptom Scale. Schizophrenia Research, 2019, 204, 452-454.	2.0	5
142	Early versus late stage schizophrenia. What markers make the difference?. World Journal of Biological Psychiatry, 2019, 20, 159-165.	2.6	3
143	Diagnostic consequences of a new category of anxious depression and a reduced duration requirement for anxiety symptoms in the ICD-11 PHC. Journal of Affective Disorders, 2019, 245, 120-125.	4.1	8
144	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. Psychological Medicine, 2019, 49, 1378-1391.	4.5	69

#	Article	IF	CITATIONS
145	<i>>5-HTTLPR–</i> brain-derived neurotrophic factor (<i>BDNF</i>) gene interactions and early adverse life events effect on impulsivity in suicide attempters. World Journal of Biological Psychiatry, 2019, 20, 137-149.	2.6	17
146	¿Pueden ser la interleucina-2 y la interleucina-1β biomarcadores especÃficos de la sintomatologÃa negativa en la esquizofrenia?. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 9-16.	1.8	8
147	Factores asociados con consumo de tabaco en pacientes con depresión. Revista De Psicologia De La Salud, 2019, 31, 298.	0.5	12
148	Prevention of recurrent suicidal behavior: Case management and psychoeducation. Psicothema, 2019, 31, 107-113.	0.9	5
149	Factores predictores del consumo de alcohol en adolescentes: datos de un estudio prospectivo de 1 año de seguimiento. Revista De Psicologia De La Salud, 2019, 31, 52-63.	0.5	2
150	Consumo de cannabis y alteraciones cognitivas en esquizofrenia y primeros episodios psicóticos. Revista De Psicologia De La Salud, 2019, 31, 89.	0.5	2
151	Tratamiento farmacológico del trastorno obsesivo-compulsivo en adultos: una guÃa de práctica clÃnica basada en el método ADAPTE. Revista De PsiquiatrÃa Y Salud Mental, 2019, 12, 77-91.	1.8	5
152	¿Mejora la CIE-11 los propósitos epidemiológicos y nosológicos de los Trastornos mentales, del comportamiento y del desarrollo?. Revista De Psicologia De La Salud, 2019, 31, 183.	0.5	3
153	Validación española de la escala de evaluación de los sÃntomas negativos-16 (NSA-16) en pacientes con esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 169-175.	1.8	5
154	The Network Structure of Schizotypal Personality Traits. Schizophrenia Bulletin, 2018, 44, S468-S479.	4.3	52
155	Smoking does not impact social and non-social cognition in patients with first episode psychosis. Schizophrenia Research, 2018, 199, 64-74.	2.0	13
156	A cost-effectiveness analysis of school-based suicide prevention programmes. European Child and Adolescent Psychiatry, 2018, 27, 1295-1304.	4.7	30
157	Association between genetic variation in the myo-inositol monophosphatase 2 (IMPA2) gene and age at onset of bipolar disorder. Journal of Affective Disorders, 2018, 232, 229-236.	4.1	8
158	ls cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?. Psychological Medicine, 2018, 48, 2247-2256.	4.5	40
159	Biomarcadores de estrés oxidativo y dimensiones clÃnicas en los 10 primeros años de esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2018, 11, 130-140.	1.8	15
160	Inverse association between negative symptoms and body mass index in chronic schizophrenia. Schizophrenia Research, 2018, 192, 69-74.	2.0	25
161	Evolution of metabolic risk factors over a two-year period in a cohort of first episodes of psychosis. Schizophrenia Research, 2018, 193, 188-196.	2.0	50
162	Regulation of inflammatory pathways in schizophrenia: A comparative study with bipolar disorder and healthy controls. European Psychiatry, 2018, 47, 50-59.	0.2	32

JULIO BOBES

#	Article	IF	CITATIONS
163	Brief assessment of schizotypal traits: A multinational study. Schizophrenia Research, 2018, 197, 182-191.	2.0	52
164	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. JAMA Psychiatry, 2018, 75, 36.	11.0	235
165	S240. DETERMINANT FACTORS OF REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S420-S420.	4.3	0
166	T17. OXIDATIVE STRESS BIOMARKERS AND NEGATIVE DIMENSION IN THE FIRST TEN YEARS OF SCHIZOPHRENIA: A 1-YEAR FOLLOW-UP STUDY. Schizophrenia Bulletin, 2018, 44, S119-S119.	4.3	0
167	Obstetric Phenotypes in the Heterogeneity of Schizophrenia. Journal of Nervous and Mental Disease, 2018, 206, 882-886.	1.0	18
168	Psychopathology is associated with reproductive health risk in European adolescents. Reproductive Health, 2018, 15, 186.	3.1	15
169	Elevated C-reactive protein as a predictor of a random one-year clinical course in the first ten years of schizophrenia. Psychiatry Research, 2018, 269, 688-691.	3.3	7
170	F12. INFLAMMATORY BIOMARKERS AND COGNITION IN FIRST EPISODE PSYCHOSIS: GENDER DIFFERENCES. Schizophrenia Bulletin, 2018, 44, S222-S223.	4.3	0
171	Characterizing decision-making and reward processing in bipolar disorder: A cluster analysis. European Neuropsychopharmacology, 2018, 28, 863-874.	0.7	16
172	Genome wide analysis of rare copy number variations in alcohol abuse or dependence. Journal of Psychiatric Research, 2018, 103, 212-218.	3.1	8
173	Oxidative stress biomarkers and clinical dimensions in first 10 years of schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2018, 11, 130-140.	0.3	7
174	Spanish validation of the Negative Symptom Assessment-16 (NSA-16) in patients with schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2018, 11, 169-175.	0.3	0
175	Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study. European Psychiatry, 2018, 52, 85-94.	0.2	17
176	Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry,the, 2018, 5, 797-807.	7.4	141
177	Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis. International Journal of Neuropsychopharmacology, 2018, 21, 410-422.	2.1	13
178	Comorbidity of Physical and Anxiety Symptoms in Adolescent: Functional Impairment, Self-Rated Health and Subjective Well-Being. International Journal of Environmental Research and Public Health, 2018, 15, 1698.	2.6	28
179	Correlates of sexual initiation among European adolescents. PLoS ONE, 2018, 13, e0191451.	2.5	32
180	Análisis de decisión multicriterio en programas de tratamiento de sustitución de opiáceos en trastornos por consumo de opiáceos. Revista De Psicologia De La Salud, 2018, 30, 167.	0.5	2

#	Article	IF	CITATIONS
181	Physical activity in European adolescents and associations with anxiety, depression and well-being. European Child and Adolescent Psychiatry, 2017, 26, 111-122.	4.7	358
182	Evidence-based national suicide prevention taskforce in Europe: A consensus position paper. European Neuropsychopharmacology, 2017, 27, 418-421.	0.7	45
183	Do patients with bipolar disorder and subsyndromal symptoms benefit from functional remediation? A 12-month follow-up study. European Neuropsychopharmacology, 2017, 27, 350-359.	0.7	26
184	The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. Schizophrenia Research, 2017, 189, 84-90.	2.0	49
185	Intuitive pharmacogenetic dosing of risperidone according to CYP2D6 phenotype extrapolated from genotype in a cohort of first episode psychosis patients. European Neuropsychopharmacology, 2017, 27, 647-656.	0.7	13
186	Factors associated with different smoking status in European adolescents: results of the SEYLE study. European Child and Adolescent Psychiatry, 2017, 26, 1319-1329.	4.7	27
187	Risky Drinkers Underestimate their Own Alcohol Consumption. Alcohol and Alcoholism, 2017, 52, 516-517.	1.6	12
188	Primary care physicians' use of the proposed classification of common mental disorders for ICD-11. Family Practice, 2017, 34, 574-580.	1.9	7
189	Bullying Victimization and Suicide Ideation and Behavior Among Adolescents in Europe: A 10-Country Study. Journal of Adolescent Health, 2017, 61, 179-186.	2.5	167
190	Suicidio, desempleo y recesión económica en España. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 70-77.	1.8	33
191	EPICOG-SCH: A brief battery to screen cognitive impact of schizophrenia in stable outpatients. Schizophrenia Research: Cognition, 2017, 8, 7-20.	1.3	2
192	Suicide, unemployment, and economic recession in Spain. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2017, 10, 70-77.	0.3	13
193	Variaciones en las concentraciones plasmÃ _i ticas de clozapina en pacientes con esquizofrenia y trastorno esquizoafectivo. Revista De PsiquiatrÃ a Y Salud Mental, 2017, 10, 192-196.	1.8	12
194	Impact of childhood trauma on cognitive profile in bipolar disorder. Bipolar Disorders, 2017, 19, 363-374.	1.9	49
195	Is it Feasible and Effective to Help Patients with Severe Mental Disorders to Quit Smoking?. European Psychiatry, 2017, 41, S32-S33.	0.2	0
196	Recomendaciones preventivas sobre el uso de ácido valproico en mujeres embarazadas o con capacidad de gestación para tener muy presentes. Revista De PsiquiatrÃa Y Salud Mental, 2017, 10, 129-133.	1.8	5
197	Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opinion on Pharmacotherapy, 2017, 18, 1987-1999.	1.8	96
198	Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2017, 10, 192-196.	0.3	6

#	Article	IF	CITATIONS
199	Why prudence is needed when interpreting articles reporting clinical trial results in mental health. Trials, 2017, 18, 143.	1.6	10
200	Psychosis risk screening: Validation of the youth psychosis atâ€risk questionnaire – brief in a communityâ€derived sample of adolescents. International Journal of Methods in Psychiatric Research, 2017, 26, .	2.1	11
201	Mental health difficulties and suicidal behaviours among young migrants: multicentre study of European adolescents. BJPsych Open, 2017, 3, 291-299.	0.7	21
202	Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry, 2017, 17, 250.	2.6	148
203	Tabaco y rendimiento cognitivo en pacientes con esquizofrenia: diseño del estudio COGNICO. Revista De Psicologia De La Salud, 2017, 29, 6.	0.5	4
204	Uso y abuso de sustancias psicotrópicas e internet, psicopatologÃa e ideación suicida en adolescentes. Revista De Psicologia De La Salud, 2017, 29, 97.	0.5	51
205	Persistent Negative Symptoms in First-Episode Psychosis. Journal of Clinical Psychiatry, 2017, 78, 1414-1422.	2.2	28
206	Treatments for Opioid Dependence and Methadone. , 2016, , 595-602.		0
207	Pathological Internet Use and Risk-Behaviors among European Adolescents. International Journal of Environmental Research and Public Health, 2016, 13, 294.	2.6	105
208	Cognitive reserve in bipolar disorder: relation to cognition, psychosocial functioning and quality of life. Acta Psychiatrica Scandinavica, 2016, 133, 386-398.	4.5	103
209	Clinical features, impulsivity, temperament and functioning and their role in suicidality in patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2016, 133, 266-276.	4.5	35
210	Differential blood-based biomarkers of psychopathological dimensions of schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 219-227.	0.3	6
211	Smoking cessation programs for persons with schizophrenia: An urgent unmet need. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 181-184.	0.3	3
212	Programas de cesación tabáquica para personas con esquizofrenia: una necesidad urgente no cubierta. Revista De PsiquiatrÃa Y Salud Mental, 2016, 9, 181-184.	1.8	13
213	Inflammatory and metabolic biomarkers of psychopathological dimensions of schizophrenia. European Psychiatry, 2016, 33, s250-s250.	0.2	1
214	Effects of functional remediation on neurocognitively impaired bipolar patients: enhancement of verbal memory. Psychological Medicine, 2016, 46, 291-301.	4.5	43
215	Trastorno obsesivo-compulsivo: utilidad de una guÃa terapéutica farmacológica. Revista De PsiquiatrÃa Y Salud Mental, 2016, 9, 131-133.	1.8	4
216	Obsessive–compulsive disorder: The usefulness of a pharmacological practice guideline. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 131-133.	0.3	0

#	Article	IF	CITATIONS
217	Multiple somatic symptoms in primary care: A field study for ICD-11 PHC, WHO's revised classification of mental disorders in primary care settings. Journal of Psychosomatic Research, 2016, 91, 48-54.	2.6	33
218	Biomarcadores sanguÃneos diferenciales de las dimensiones psicopatológicas de la esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2016, 9, 219-227.	1.8	21
219	Validation of a Spanish version of the Columbia-Suicide Severity Rating Scale (C-SSRS). Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2016, 9, 134-142.	0.3	19
220	Cognition and psychopathology in first-episode psychosis: are they related to inflammation?. Psychological Medicine, 2016, 46, 2133-2144.	4.5	36
221	Effectiveness of pharmacogenetic information in the treatment of major depressive disorder: results from the AB-GEN randomized clinical trial. European Neuropsychopharmacology, 2016, 26, S404-S405.	0.7	1
222	Métodos de exploración de la función cognitiva en la práctica clÃnica. Psiquiatria Biologica, 2016, 23, 29-33.	0.1	14
223	Suicide prevention strategies revisited: 10-year systematic review. Lancet Psychiatry,the, 2016, 3, 646-659.	7.4	1,160
224	Pathological Internet Use Is on the Rise Among European Adolescents. Journal of Adolescent Health, 2016, 59, 236-239.	2.5	57
225	Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes. Pharmacogenomics Journal, 2016, 16, 439-445.	2.0	30
226	Childhood trauma in suicide attempters: Case-control study. European Psychiatry, 2016, 33, S111-S111.	0.2	2
227	Effects of nicotine abstinence on clinical symptoms. Study at 3 and 6-months follow-up of outpatients with schizophrenia. European Psychiatry, 2016, 33, s261-s262.	0.2	1
228	Psychometric properties of a Spanish-version of the Schizophrenia Objective Functioning Instrument (Sp-SOFI). International Journal of Clinical and Health Psychology, 2016, 16, 58-75.	5.1	5
229	Validación de la versión en español de la Columbia-Suicide Severity Rating Scale (Escala Columbia para) Tj ET	Qq1 1 0.7 1.8	84314 rgBT
230	It is feasible and effective to help patients with severe mental disorders to quit smoking: An ecological pragmatic clinical trial with transdermal nicotine patches and varenicline. Schizophrenia Research, 2016, 176, 272-280.	2.0	22
231	Antipsychotic switching in schizoaffective disorder: A systematic review. World Journal of Biological Psychiatry, 2016, 17, 495-513.	2.6	17
232	Association between victimization by bullying and direct self injurious behavior among adolescence in Europe: a ten-country study. European Child and Adolescent Psychiatry, 2016, 25, 1183-1193.	4.7	62
233	A Pharmacovigilance Study in First Episode of Psychosis: Psychopharmacological Interventions and Safety Profiles in the PEPs Project. International Journal of Neuropsychopharmacology, 2016, 19, pyv121.	2.1	29
234	Reasons for Attempted Suicide in Europe: Prevalence, Associated Factors, and Risk of Repetition. Archives of Suicide Research, 2016, 20, 45-58.	2.3	38

#	Article	IF	CITATIONS
235	Functional remediation in bipolar disorder: 1-year follow-up of neurocognitive and functional outcome. British Journal of Psychiatry, 2016, 208, 87-93.	2.8	95
236	Opposite Cannabis-Cognition Associations in Psychotic Patients Depending on Family History. PLoS ONE, 2016, 11, e0160949.	2.5	22
237	El alcoholismo y su abordaje desde una perspectiva ciudadana. Revista De Psicologia De La Salud, 2016, 28, 163.	0.5	7
238	Diferencias de género en la gravedad de la adicción. Revista De Psicologia De La Salud, 2016, 28, 221.	0.5	14
239	A Review of Quality-of-Life Assessment Measures in Schizophrenia: Limitations and Future Developments. , 2016, , 65-77.		Ο
240	Exploring Genetic Variability at PI, GSK3, HPA, and Glutamatergic Pathways in Lithium Response. Journal of Clinical Psychopharmacology, 2015, 35, 600-604.	1.4	20
241	Reading Books and Watching Films as a Protective Factor against Suicidal Ideation. International Journal of Environmental Research and Public Health, 2015, 12, 15937-15942.	2.6	10
242	Cognitive Performance associated to functional outcomes in stable outpatients with schizophrenia. Schizophrenia Research: Cognition, 2015, 2, 146-158.	1.3	19
243	Predictors of Posttreatment Drinking Outcomes in Patients with Alcohol Dependence. European Addiction Research, 2015, 21, 19-30.	2.4	11
244	Pathological Internet use among adolescents: Comparing gamers and non-gamers. Psychiatry Research, 2015, 228, 128-135.	3.3	117
245	Pro-/Antiinflammatory Dysregulation in Early Psychosis: Results from a 1-Year Follow-Up Study. International Journal of Neuropsychopharmacology, 2015, 18, pyu037-pyu037.	2.1	26
246	Assessing and Treating Alcohol Relapse Risk in Liver Transplantation Candidates. Alcohol and Alcoholism, 2015, 50, 164-172.	1.6	40
247	Help-seeking behaviour following school-based screening for current suicidality among European adolescents. Social Psychiatry and Psychiatric Epidemiology, 2015, 50, 973-982.	3.1	30
248	Risk Factors and Comorbidities for Occasional and Daily Smoking in European Adolescents: Results of the Seyle Project. European Psychiatry, 2015, 30, 515.	0.2	1
249	Differential Biomarkers of Negative Dimension in Schizophrenia. European Psychiatry, 2015, 30, 1697.	0.2	1
250	Premorbid adjustment and clinical correlates of cognitive impairment in first-episode psychosis. The PEPsCog Study. Schizophrenia Research, 2015, 164, 65-73.	2.0	92
251	Predictive factors of functional capacity and real-world functioning in patients with schizophrenia. European Psychiatry, 2015, 30, 622-627.	0.2	40
252	School-based suicide prevention programmes: the SEYLE cluster-randomised, controlled trial. Lancet, The, 2015, 385, 1536-1544.	13.7	452

#	Article	IF	CITATIONS
253	How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview. Acta Psychiatrica Scandinavica, 2015, 132, 122-130.	4.5	42
254	Psychometric evaluation of the negative syndrome of schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2015, 265, 559-566.	3.2	50
255	The negative syndrome of schizophrenia: Three -underlying components are better than two. Schizophrenia Research, 2015, 166, 115-118.	2.0	18
256	Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms. European Neuropsychopharmacology, 2015, 25, 257-264.	0.7	52
257	Factors Associated with Hospitalization after Suicide Spectrum Behaviors: Results from a Multicenter Study in Spain. Archives of Suicide Research, 2015, 19, 17-34.	2.3	15
258	Effectiveness of a Multi-Component Smoking Cessation Support Programme (McSCSP) for Patients with Severe Mental Disorders: Study Design. International Journal of Environmental Research and Public Health, 2014, 11, 373-389.	2.6	6
259	Alcohol Consumption Patterns among Adolescents are Related to Family Structure and Exposure to Drunkenness within the Family: Results from the SEYLE Project. International Journal of Environmental Research and Public Health, 2014, 11, 12700-12715.	2.6	25
260	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
261	Immigration and recommended care after a suicide attempt in Europe: equity or bias?. European Journal of Public Health, 2014, 24, 63-65.	0.3	5
262	Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?. British Journal of Clinical Pharmacology, 2014, 77, 272-284.	2.4	36
263	Pharmacogenetic study of second-generation antipsychotic long-term treatment metabolic side effects (the SLiM Study): Rationale, objectives, design and sample description. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 166-178.	0.3	5
264	Spanish consensus on the physical health of patients with depressive disorders. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 195-207.	0.3	5
265	Effect of one year of a gluten-free diet on the clinical evolution of irritable bowel syndrome plus fibromyalgia in patients with associated lymphocytic enteritis: a case-control study. Arthritis Research and Therapy, 2014, 16, 421.	3.5	16
266	Antipsychotic switching in bipolar disorders: a systematic review. International Journal of Neuropsychopharmacology, 2014, 17, 497-507.	2.1	25
267	Teacher satisfaction with school and psychological well-being affects their readiness to help children with mental health problems. Health Education Journal, 2014, 73, 382-393.	1.2	81
268	Treatment adherence and quality of sleep in schizophrenia outpatients. International Journal of Psychiatry in Clinical Practice, 2014, 18, 70-76.	2.4	30
269	Prevención del suicidio en España: una necesidad clÃnica no resuelta. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 1-4.	1.8	36
270	Risk-behaviour screening for identifying adolescents with mental health problems in Europe. European Child and Adolescent Psychiatry, 2014, 23, 611-620.	4.7	60

#	Article	IF	CITATIONS
271	Response to â€~Remarkable prevalence of celiac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study' – authors' reply. Arthritis Research and Therapy, 2014, 16, 403.	3.5	0
272	Hours of sleep in adolescents and its association with anxiety, emotional concerns, and suicidal ideation. Sleep Medicine, 2014, 15, 248-254.	1.6	144
273	Consenso español de salud fÃsica del paciente con depresión. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 195-207.	1.8	16
274	Estudio farmacogenético del tratamiento a largo plazo con antipsicóticos de segunda generación y sus efectos adversos metabólicos (Estudio SLiM): justificación, objetivos, diseño y descripción de la muestra. Revista De PsiquiatrÃa Y Salud Mental, 2014, 7, 166-178.	1.8	9
275	Study protocol of a prevention of recurrent suicidal behaviour program based on case management (PSyMAC). Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 131-138.	0.3	3
276	Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2014, 7, 113-120.	0.3	2
277	Lifeâ€ŧime prevalence and psychosocial correlates of adolescent direct selfâ€ɨnjurious behavior: A comparative study of findings in 11 European countries. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2014, 55, 337-348.	5.2	298
278	Pathological Internet use among European adolescents: psychopathology and self-destructive behaviours. European Child and Adolescent Psychiatry, 2014, 23, 1093-1102.	4.7	184
279	P.6.d.014 Psychopathological tolerability of varenicline and nicotine patches for smoking cessation in severe mental disorders. European Neuropsychopharmacology, 2014, 24, S694.	0.7	0
280	Replication of previous genome-wide association studies of psychiatric diseases in a large schizophrenia case–control sample from Spain. Schizophrenia Research, 2014, 159, 107-113.	2.0	36
281	Verbal memory as a mediator in the relationship between subthreshold depressive symptoms and functional outcome in bipolar disorder. Journal of Affective Disorders, 2014, 160, 50-54.	4.1	71
282	Suicide prevention in Spain: An uncovered clinical need. Revista De PsiquiatrÃa Y Salud Mental (English) Tj ETQq	0.0.1gBT	/Oyerlock 10
283	EPA Guidance on Tobacco Dependence and Strategies for Smoking Cessation in People with Mental Illness. European Psychiatry, 2014, 29, 65-82.	0.2	119
284	Spanish adaptation and validation of the Brief Negative Symptoms Scale. Comprehensive Psychiatry, 2014, 55, 1726-1729.	3.1	54
285	Association between GSK3β gene and increased impulsivity in bipolar disorder. European Neuropsychopharmacology, 2014, 24, 510-518.	0.7	25
286	PatologÃa dual en trastornos de ansiedad: recomendaciones en el tratamiento farmacológico. Revista De Psicologia De La Salud, 2014, 26, 254.	0.5	8
287	Effects of the economic crisis on demand due to mental disorders in Asturias: data from the Asturias Cumulative Psychiatric Case Register (2000-2010). Actas Espanolas De Psiquiatria, 2014, 42, 108-15.	0.1	16
288	Child coping, parent coping assistance, and postâ€ŧraumatic stress following paediatric physical injury. Child: Care, Health and Development, 2013, 39, 171-177.	1.7	42

#	Article	IF	CITATIONS
289	The Saving and Empowering Young Lives in Europe (SEYLE) Randomized Controlled Trial (RCT): methodological issues and participant characteristics. BMC Public Health, 2013, 13, 479.	2.9	57
290	Guilt and depression: Two different factors in individuals with negative symptoms of schizophrenia. European Psychiatry, 2013, 28, 327-331.	0.2	19
291	Remarkable prevalence of coeliac disease in patients with irritable bowel syndrome plus fibromyalgia in comparison with those with isolated irritable bowel syndrome: a case-finding study. Arthritis Research and Therapy, 2013, 15, R201.	3.5	27
292	Clinical impact of a gluten-free diet on health-related quality of life in seven fibromyalgia syndrome patients with associated celiac disease. BMC Gastroenterology, 2013, 13, 157.	2.0	36
293	Genetic variability at IMPA2, INPP1 and GSK3β increases the risk of suicidal behavior in bipolar patients. European Neuropsychopharmacology, 2013, 23, 1452-1462.	0.7	46
294	Ante el nuevo reto de identificar el sÃndrome negativo de la esquizofrenia. Revista De PsiquiatrÃa Y Salud Mental, 2013, 6, 141-143.	1.8	17
295	The new challenge in identifying the negative syndrome of schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2013, 6, 141-143.	0.3	6
296	Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. Schizophrenia Research, 2013, 150, 421-426.	2.0	31
297	P.7.e.003 Sleep in adolescents: association with emotional problems and suicidal ideation. European Neuropsychopharmacology, 2013, 23, S613-S614.	0.7	0
298	A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. European Neuropsychopharmacology, 2013, 23, 1432-1442.	0.7	359
299	P.2.d.014 Genetic variability at IMPA2 and INPP1 genes is associated to lithium response in bipolar patients. European Neuropsychopharmacology, 2013, 23, S370-S371.	0.7	1
300	Evolución de la prevalencia administrativa de los trastornos mentales durante 13 años en Asturias (norte de España). Revista De PsiquiatrÃa Y Salud Mental, 2013, 6, 60-66.	1.8	8
301	Efficacy of Functional Remediation in Bipolar Disorder: A Multicenter Randomized Controlled Study. American Journal of Psychiatry, 2013, 170, 852-859.	7.2	269
302	Satisfaction with Life of Schizophrenia Outpatients and Their Caregivers: Differences between Patients with and without Self-Reported Sleep Complaints. Schizophrenia Research and Treatment, 2013, 2013, 1-3.	1.5	13
303	Adolescent subthresholdâ€depression and anxiety: psychopathology, functional impairment and increased suicide risk. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2013, 54, 670-677.	5.2	387
304	Switching to Ziprasidone in the Clinical Practice Setting: An Open-Label Study. International Journal of Psychiatry in Medicine, 2013, 45, 125-142.	1.8	8
305	The state of psychiatry in Spain. International Review of Psychiatry, 2012, 24, 347-355.	2.8	5
306	The cost-effectiveness of paliperidone extended release in Spain. Journal of Medical Economics, 2012, 15, 26-34.	2.1	15

#	Article	IF	CITATIONS
307	Functional impairment as a defining feature of: amnestic MCI cognitive, emotional, and demographic correlates. International Psychogeriatrics, 2012, 24, 1494-1504.	1.0	23
308	P.3.f.002 Epidemiologic naturalistic study to determine the relationship between the Personal and Social Performance (PSP) scale and the perceived sleep quality in schizophrenia. European Neuropsychopharmacology, 2012, 22, S356.	0.7	0
309	Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study. European Psychiatry, 2012, 27, 267-274.	0.2	21
310	Pregabalin for the discontinuation of long-term benzodiazepines use: An assessment of its effectiveness in daily clinical practice. European Psychiatry, 2012, 27, 301-307.	0.2	43
311	Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression. European Psychiatry, 2012, 27, 114-128.	0.2	39
312	Recommendations for the prevention and management of suicidal behaviour. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2012, 5, 8-23.	0.3	2
313	Psychometric properties of the Spanish version of the Body Weight, Image and Self-Esteem Evaluation questionnaire in patients with severe mental disorders. Comprehensive Psychiatry, 2012, 53, 1237-1242.	3.1	3
314	Suicide prevention for youth - a mental health awareness program: lessons learned from the Saving and Empowering Young Lives in Europe (SEYLE) intervention study. BMC Public Health, 2012, 12, 776.	2.9	62
315	New treatment guidelines for acute bipolar mania: A critical review. Journal of Affective Disorders, 2012, 140, 125-141.	4.1	76
316	The role of genetic variability in the SLC6A4, BDNF and GABRA6 genes in anxietyâ€related traits. Acta Psychiatrica Scandinavica, 2012, 125, 194-202.	4.5	41
317	Prevalence of pathological internet use among adolescents in <scp>E</scp> urope: demographic and social factors. Addiction, 2012, 107, 2210-2222.	3.3	517
318	The Incidence of Hospital-Treated Attempted Suicide in Oviedo, Spain. Crisis, 2012, 33, 46-53.	1.2	20
319	Efectividad a largo plazo de los tratamientos de mantenimiento con metadona en personas con adicción a derivados opiáceos. Revista De Psicologia De La Salud, 2012, 24, 179.	0.5	5
320	Sexual dysfunction in patients with schizophrenia vs bipolar disorder. European Psychiatry, 2011, 26, 1542-1542.	0.2	0
321	Clinical meaningful outcomes in schizophrenia: remission and recovery. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2011, 4, 53-65.	0.3	7
322	Recomendaciones para el cambio de antipsicóticos. Posicionamiento de la Sociedad Española de PsiquiatrÃa y Sociedad Española de PsiquiatrÃa Biológica. Revista De PsiquiatrÃa Y Salud Mental, 2011, 4, 150-168.	1.8	26
323	Report of the 3rd European Brain Policy Forum. Revista De PsiquiatrÃa Y Salud Mental (English) Tj ETQq1 1 0.784	1314 rgBT 0.3	/Oyerlock 1

PMH33 The Cost-Effectiveness of Paliperidone ER in Spain. Value in Health, 2011, 14, A292.

0.3 0

#	Article	IF	CITATIONS
325	Disability and health-related quality of life in outpatients with generalised anxiety disorder treated in psychiatric clinics: is there still room for improvement?. Annals of General Psychiatry, 2011, 10, 7.	2.7	10
326	Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry, 2011, 10, 138-151.	10.4	631
327	A 25-year follow-up of patients admitted to methadone treatment for the first time: Mortality and gender differences. Addictive Behaviors, 2011, 36, 1184-1190.	3.0	51
328	Role of serotonergic-related systems in suicidal behavior: Data from a case–control association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1518-1524.	4.8	21
329	A cross-cultural comparison between Spain and the USA: Temperament and character distribution by sex and age. Psychiatry Research, 2011, 186, 397-401.	3.3	12
330	Interconnection between biological abnormalities in borderline personality disorder: Use of the Bayesian networks model. Psychiatry Research, 2011, 186, 315-319.	3.3	15
331	Validation of the Spanish Personal and Social Performance scale (PSP) in outpatients with stable and unstable schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2011, 4, 9-18.	0.3	21
332	Change in psychiatrists' attitudes towards the physical health care of patients with schizophrenia coinciding with the dissemination of the consensus on physical health in patients with schizophrenia. European Psychiatry, 2011, 26, 305-312.	0.2	15
333	Psychopathology, coronary heart disease and metabolic syndrome in schizophrenia spectrum patients with deficit versus non-deficit schizophrenia: Findings from the CLAMORS study. European Neuropsychopharmacology, 2011, 21, 867-875.	0.7	33
334	Self-Perceived Needs Are Related to Violent Behavior Among Schizophrenia Outpatients. Journal of Nervous and Mental Disease, 2011, 199, 666-671.	1.0	10
335	Psychometric Properties of the Spanish Version of the Changes in Sexual Functioning Questionnaire Short-Form (CSFQ-14) in Patients with Severe Mental Disorders. Journal of Sexual Medicine, 2011, 8, 1371-1382.	0.6	24
336	Validación de la versión española de la escala de Funcionamiento Personal y Social en pacientes ambulatorios con esquizofrenia estable o inestable. Revista De PsiquiatrÃa Y Salud Mental, 2011, 4, 9-18.	1.8	65
337	Resultados clÃnicos relevantes en esquizofrenia: remisión y recuperación. Revista De PsiquiatrÃa Y Salud Mental, 2011, 4, 53-65.	1.8	16
338	Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry, 2011, 10, 52-77.	10.4	1,767
339	Borderline Personality Traits in Nonclinical Young Adults. Journal of Personality Disorders, 2011, 25, 542-556.	1.4	29
340	Topiramate for the Treatment of Alcohol Dependence: Comparison with Naltrexone. European Addiction Research, 2011, 17, 29-36.	2.4	49
341	Effects of Pregabalin on Subjective Sleep Disturbance Symptoms during Withdrawal from Long-Term Benzodiazepine Use. European Addiction Research, 2011, 17, 262-270.	2.4	19
342	Negative symptoms are prevalent in antipsychotic-treated adult outpatients with schizophrenia spectrum disorders. Evidence-Based Mental Health, 2011, 13, 106-106.	4.5	1

#	Article	IF	CITATIONS
343	Necesidad de evaluación de la patologÃa dual en contexto penitenciario. Revista De Psicologia De La Salud, 2011, 23, 37.	0.5	7
344	Amisulpride en el tratamiento de la dependencia alcohólica. Revista De Psicologia De La Salud, 2011, 23, 149.	0.5	2
345	Impact of substance use on the physical health of patients with bipolar disorder. Acta Psychiatrica Scandinavica, 2010, 121, 437-445.	4.5	31
346	Interactions between functional serotonergic polymorphisms and demographic factors influence personality traits in healthy Spanish Caucasians. Psychiatric Genetics, 2010, 20, 171-178.	1.1	19
347	Sociodemographic factors associated with personality traits assessed through the TCI. Personality and Individual Differences, 2010, 48, 809-814.	2.9	9
348	Saving and Empowering Young Lives in Europe (SEYLE): a randomized controlled trial. BMC Public Health, 2010, 10, 192.	2.9	124
349	The general problem of increased somatic comorbidity in bipolar patients. Annals of General Psychiatry, 2010, 9, .	2.7	0
350	Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. International Journal of Neuropsychopharmacology, 2010, 13, 305.	2.1	116
351	Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. Schizophrenia Research, 2010, 119, 101-109.	2.0	151
352	Impact of the Spanish Consensus on Physical Health of Patients with Schizophrenia. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2010, 3, 119-127.	0.3	4
353	Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 26-31.	4.8	37
354	Measurement Invariance of the Reynolds Depression Adolescent Scale across Gender and Age. International Journal of Testing, 2010, 10, 133-148.	0.3	21
355	Narcisismo manifiesto, narcisismo encubierto y trastornos de personalidad en una Unidad de Conductas Adictivas: validez predictiva de respuesta a tratamiento. Revista De Psicologia De La Salud, 2010, 22, 107.	0.5	7
356	Validez de la versión española de la Hypersensitive Narcissism Scale (HSNS) en una Unidad de Conductas Adictivas. Revista De Psicologia De La Salud, 2010, 22, 29.	0.5	7
357	Prevalence of Negative Symptoms in Outpatients With Schizophrenia Spectrum Disorders Treated With Antipsychotics in Routine Clinical Practice. Journal of Clinical Psychiatry, 2010, 71, 280-286.	2.2	210
358	the Criteria Sets for Further Study. International Journal of Social Psychiatry, 2009, 55, 195-197.	3.1	2
359	Psychometric Properties of the Revised Physical and Social Anhedonia Scales in Non-Clinical Young Adults. Spanish Journal of Psychology, 2009, 12, 815-822.	2.1	32
360	Cardiovascular risk in patients with bipolar disorder. Journal of Affective Disorders, 2009, 115, 302-308.	4.1	68

#	Article	IF	CITATIONS
361	Violence among schizophrenia outâ€patients compliant with medication: prevalence and associated factors. Acta Psychiatrica Scandinavica, 2009, 119, 218-225.	4.5	47
362	Polymorphisms of the ILâ€l Gene Complex Are Associated With Alcohol Dependence in Spanish Caucasians: Data From an Association Study. Alcoholism: Clinical and Experimental Research, 2009, 33, 2147-2153.	2.4	19
363	Differential role of serotonergic polymorphisms in alcohol and heroin dependence. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 695-700.	4.8	35
364	Remission in schizophrenia: Results from a 1-year follow-up observational study. Schizophrenia Research, 2009, 108, 214-222.	2.0	50
365	Recovery from schizophrenia: Results from a 1-year follow-up observational study of patients in symptomatic remission. Schizophrenia Research, 2009, 115, 58-66.	2.0	75
366	Spanish Consensus on Physical Health in Patients with Bipolar Disorder [PW05-04]. European Psychiatry, 2009, 24, .	0.2	0
367	Substance Use and Physical Health in Patients with Bipolar Disorder Under Maintenance Treatment. European Psychiatry, 2009, 24, .	0.2	1
368	Cardiovascular and Respiratory Comorbidities in Patients with Bipolar Disorder: A Systematic Review. European Psychiatry, 2009, 24, .	0.2	0
369	Nutritional, Metabolic and Endocrine Disorders in Patients with Bipolar Disorder: A Systematic Review. European Psychiatry, 2009, 24, .	0.2	Ο
370	Gynaecological and Obstetric Comorbidities in Patients with Bipolar Disorder: A Systematic Review. European Psychiatry, 2009, 24, .	0.2	0
371	Spanish Consensus on Physical Health in Patients with Bipolar Disorder [P01-205]. European Psychiatry, 2009, 24, .	0.2	0
372	Implicación de polimorfismos serotoninérgicos en la gravedad clÃnica del trastorno de pánico. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 35-41.	1.8	5
373	Rendimiento psicométrico del Cuestionario Oviedo de Sueño en pacientes con trastorno mental grave. Revista De PsiquiatrÃa Y Salud Mental, 2009, 2, 169-177.	1.8	21
374	Role of serotonergic polymorphisms in the clinical severity of the panic disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2009, 2, 35-41.	0.3	1
375	Psychometric performance of the Oviedo Sleep Questionnaire in patients with severe mental disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2009, 2, 169-177.	0.3	6
376	P.2.e.009 Gynaecological and obstetric comorbidities in patients with bipolar disorder: a systematic review. European Neuropsychopharmacology, 2009, 19, S453-S454.	0.7	0
377	P.3.a.025 Influence of knowledge of the Spanish consensus on physical health in schizophrenic patients in clinical practice. European Neuropsychopharmacology, 2009, 19, S494-S495.	0.7	0
378	P.6.c.005 Benzodiazepines use withdrawal tapering gradually with pregabalin: findings from the medical practice. European Neuropsychopharmacology, 2009, 19, S652.	0.7	2

#	Article	IF	CITATIONS
379	Prevalence of Metabolic Syndrome and Coronary Heart Disease Risk in Patients with Schizoaffective Disorder: Clamors Study. European Psychiatry, 2009, 24, .	0.2	0
380	Differences in Personality Traits Evaluated by TCI According to Physical Illness. European Psychiatry, 2009, 24, .	0.2	0
381	Evaluation of symptomatology on schizophrenia. Medical Psychiatry, 2009, , 32-38.	0.2	0
382	Validity and reliability of the Spanish versions of the Bechâ€Rafaelsen's mania and melancholia scales for bipolar disorders. Acta Psychiatrica Scandinavica, 2008, 117, 207-215.	4.5	6
383	Using Topiramate or Naltrexone for the Treatment of Alcoholâ€Dependent Patients. Alcoholism: Clinical and Experimental Research, 2008, 32, 1251-1259.	2.4	64
384	The prevalence of metabolic syndrome in patients with bipolar disorder. Journal of Affective Disorders, 2008, 106, 197-201.	4.1	107
385	Concordance of standard and modified NCEP ATP III criteria for identification of metabolic syndrome in outpatients with schizophrenia treated with antipsychotics: A corollary from the CLAMORS study. Schizophrenia Research, 2008, 99, 23-28.	2.0	21
386	A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study. Schizophrenia Research, 2008, 104, 1-12.	2.0	74
387	Consenso Español de Salud FÃsica del Paciente con Trastorno Bipolar. Revista De PsiquiatrÃa Y Salud Mental, 2008, 1, 26-37.	1.8	33
388	Spanish Consensus on Physical Health of Patients With Bipolar Disorder. Revista De PsiquiatrÃa Y Salud Mental (English Edition), 2008, 1, 26-37.	0.3	5
389	Is attempted suicide different in adolescent and adults?. Psychiatry Research, 2008, 157, 131-137.	3.3	49
390	Association study between obsessive–compulsive disorder and serotonergic candidate genes. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 765-770.	4.8	47
391	A simulation model to estimate the coronary heart disease risk in schizophrenic patients treated with second-generation-antipsychotic drugs: A Spanish perspective. European Psychiatry, 2008, 23, S139.	0.2	0
392	Association between Heroin Dependence and 5-HT _{2A} Receptor Gene Polymorphisms. European Addiction Research, 2008, 14, 47-52.	2.4	20
393	Association Between the Stin2 VNTR Polymorphism of the Serotonin Transporter Gene and Treatment Outcome in Alcohol-Dependent Patients. Alcohol and Alcoholism, 2008, 43, 516-522.	1.6	26
394	Association study of the interleukin-1 gene complex and tumor necrosis factor alpha gene with suicide attempts. Psychiatric Genetics, 2008, 18, 147-150.	1.1	11
395	Association between the A-1438G polymorphism of the serotonin 2A receptor gene and nonimpulsive suicide attempts. Psychiatric Genetics, 2008, 18, 213-218.	1.1	29
	RemisiÃ ³ n sintomÃ;tica y funcionamiento social/profesional en pacientes con esquizofrenia tratados		

RemisiÃ³n sintomÃ_itica y funcionamiento social/profesional en pacientes con esquizofrenia tratados ambulatoriamente: prevalencia y asociaciones en un estudio transversal. European Psychiatry (Ed) Tj ETQq0 0 0 rgBT.¢Overlo¢k 10 Tf 50

#	Article	IF	CITATIONS
397	The "Seroquel―Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia. International Journal of Psychiatry in Clinical Practice, 2007, 11, 222-232.	2.4	0
398	The sufficiency of the HAM-D6as an outcome instrument in the acute therapy of antidepressants in the outpatient setting. International Journal of Psychiatry in Clinical Practice, 2007, 11, 146-150.	2.4	5
399	Association study of serotonin 2A receptor (5-HT2A) and serotonin transporter (5-HTT) gene polymorphisms with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2007, 31, 741-745.	4.8	38
400	Schizophrenia and overweight/obesity: Pathophysiology and medical consequences. European Psychiatry, 2007, 22, S94.	0.2	0
401	Do brain imaging and neurophysiology differentiate borderline personality disorder and depression?. European Psychiatry, 2007, 22, S35.	0.2	1
402	Consensus guideline for the evaluation of physical health in patients with schizophrenia. European Psychiatry, 2007, 22, S105.	0.2	1
403	Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study. European Psychiatry, 2007, 22, 490-498.	0.2	105
404	P.3.c.037 Neuropsychological performance and cognitive disability in schizophrenia outpatients. European Neuropsychopharmacology, 2007, 17, S445-S446.	0.7	0
405	Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study. Schizophrenia Research, 2007, 90, 162-173.	2.0	177
406	Lack of association between endothelial nitric oxide synthase (NOS3) gene polymorphisms and suicide attempts. Behavioral and Brain Functions, 2007, 3, 32.	3.3	6
407	Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD). Journal of Affective Disorders, 2007, 102, 93-99.	4.1	45
408	Quality of Life in Obsessive-Compulsive Disorder. , 2007, , 293-303.		4
409	Quality of life in schizophrenic patients. Dialogues in Clinical Neuroscience, 2007, 9, 215-226.	3.7	128
410	P.3.c.050 Psychopathology and metabolic syndrome (MS) in psychotic patients: the CLAMORS study. European Neuropsychopharmacology, 2006, 16, S423-S424.	0.7	0
411	Negative evidences in association between apolipoprotein E polymorphism and panic disorder. European Psychiatry, 2006, 21, 59-61.	0.2	5
412	Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. European Psychiatry, 2006, 21, 34-40.	0.2	70
413	N-acetyltransferase-2 polymorphisms and schizophrenia. European Psychiatry, 2006, 21, 333-337.	0.2	5
414	Interleukin-1 Gene Complex in Schizophrenia: An Association Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 678-680.	1.7	12

#	Article	IF	CITATIONS
415	Neurologic Soft Signs in Borderline Personality Disorder. Journal of Clinical Psychiatry, 2006, 67, 541-546.	2.2	19
416	Psychometric properties of the Spanish version of the screening scale for DSM-IV Generalized Anxiety Disorder of Carroll and Davidson. Actas Espanolas De Psiquiatria, 2006, 34, 83-93.	0.1	4
417	PMH41 REMISSION CRITERIA FOR DEPRESSION WHEN USING SHORT VERSIONS OF THE HAMILTON DEPRESSION RATING SCALE (HDRS). Value in Health, 2005, 8, A208.	0.3	0
418	Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 944-951.	4.8	10
419	Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: a multivariate analysis of a large naturalistic study in the hospital setting. Medicina ClÃnica, 2005, 124, 481-486.	0.6	3
420	Quality of life measures in schizophrenia. European Psychiatry, 2005, 20, S313-S317.	0.2	79
421	Serotonin gene polymorphisms in patients with panic disorder. Actas Espanolas De Psiquiatria, 2005, 33, 210-5.	0.1	21
422	Evaluation of the Two-Way Communication Checklist as a clinical intervention. British Journal of Psychiatry, 2004, 184, 79-83.	2.8	57
423	Managing acute exacerbations of schizophrenia: focus on quetiapine. Current Medical Research and Opinion, 2004, 20, 619-626.	1.9	33
424	Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004, 28, 1287-1297.	4.8	29
425	Is the biological nature of depressive symptoms in borderline patients without concomitant Axis I pathology idiosyncratic? Sleep EEG comparison with recurrent brief, major depression and control subjects. Psychiatry Research, 2004, 129, 65-73.	3.3	28
426	Psychosocial factors associated with cancer behavioural risk in relatives of cancer patients. European Journal of Cancer Prevention, 2004, 13, 105-111.	1.3	3
427	Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addiction Biology, 2003, 8, 429-438.	2.6	39
428	Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophrenia Research, 2003, 62, 77-88.	2.0	113
429	Predictors of number and severity of violence episodes in a one-year follow-up schizophrenia sample. Schizophrenia Research, 2003, 60, 333.	2.0	0
430	Patterns of use of olanzapine in the inpatient treatment of acute schizophrenia: A multivariate approach of the EUROPA study. Schizophrenia Research, 2003, 60, 278.	2.0	0
431	Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study. European Neuropsychopharmacology, 2003, 13, 39-48.	0.7	17
432	Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003, 27, 473-481.	4.8	36

#	Article	IF	CITATIONS
433	Frequency of Sexual Dysfunction and Other Reproductive Side-effects in Patients with Schizophrenia Treated with Risperidone, Olanzapine, Quetiapine, or Haloperidol: The Results of the EIRE Study. Journal of Sex and Marital Therapy, 2003, 29, 125-147.	1.5	178
434	Use of Cocaine by Secondary School Students in Northern Spain. European Addiction Research, 2003, 9, 138-143.	2.4	11
435	Evaluación psicométrica comparativa de las versiones en español de 6, 17 y 21 Ãŧems de la Escala de valoración de Hamilton para la evaluación de la depresión. Medicina ClÃnica, 2003, 120, 693-700.	0.6	20
436	Validación de las versiones en español de la Clinical Anxiety Scale y del Physician Questionnaire para la evaluación de los trastornos de ansiedad. Medicina ClÃnica, 2003, 121, 367-374.	0.6	2
437	Evaluating Changes in Sexual Functioning in Depressed Patients: Sensitivity to Change of the CSFQ. Journal of Sex and Marital Therapy, 2002, 28, 93-103.	1.5	24
438	Apolipoprotein E genotype and schizophrenia: further negative evidence. Acta Psychiatrica Scandinavica, 2002, 105, 71-75.	4.5	14
439	Use of MDMA and Other Illicit Drugs by Young Adult Males in Northern Spain. European Addiction Research, 2002, 8, 147-154.	2.4	29
440	Effects of Carbamazepine on Dexamethasone Suppression and Sleep Electroencephalography in Borderline Personality Disorder. Neuropsychobiology, 2002, 45, 113-119.	1.9	10
441	Treatment of severely psychotic inpatients with schizophrenia: olanzapine versus other antipsychotic drugs. International Clinical Psychopharmacology, 2002, 17, 287-295.	1.7	5
442	Is antipsychotic-induced weight gain related to sexual dysfunction?. European Neuropsychopharmacology, 2002, 12, 282-283.	0.7	0
443	Effectiveness and safety of olanzapine versus conventional antipsychotics in the treatment of inpatient with acute schizophrenia: A multivariate analysis. European Neuropsychopharmacology, 2002, 12, 303.	0.7	0
444	Frequency of Extrapyramidal Adverse Reactions in Schizophrenic Outpatients Treated with Risperidone, Olanzapine, Quetiapine or Haloperidol. Clinical Drug Investigation, 2002, 22, 609-622.	2.2	9
445	Biological nature of depressive symptoms in borderline personality disorder: endocrine comparison to recurrent brief and major depression. Journal of Psychiatric Research, 2002, 36, 137-145.	3.1	25
446	2-COM: an instrument to facilitate patient-professional communication in routine clinical practice. Acta Psychiatrica Scandinavica, 2002, 106, 446-452.	4.5	23
447	24â€Hour opiate detoxification and antagonist induction at home–the â€~Asturian method': a report on 1368 procedures. Addiction Biology, 2002, 7, 243-250.	2.6	18
448	High Degree of Tolerability for Monotherapy With High Doses of Quetiapine. Journal of Clinical Psychiatry, 2002, 63, 1048-1049.	2.2	11
449	Quality of life and disability in patients with obsessive-compulsive disorder. European Psychiatry, 2001, 16, 239-245.	0.2	201
450	Sleep-EEG in borderline patients without concomitant major depression: a comparison with major depressives and normal control subjects. Psychiatry Research, 2001, 105, 87-95.	3.3	47

#	Article	IF	CITATIONS
451	Current status of quality of life assessment in schizophrenic patients. European Archives of Psychiatry and Clinical Neuroscience, 2001, 251, 38-42.	3.2	15
452	Evolución de la gravedad de la adicción a los dos años de tratamiento en pacientes heroinómanos. Revista De Psicologia De La Salud, 2001, 13, 51.	0.5	3
453	Calidad de vida y discapacidad en pacientes con trastorno obsesivo-compulsivo. European Psychiatry (Ed Española), 2001, 8, 436-442.	0.0	0
454	Developments in the treatment of drug dependence. Current Opinion in Psychiatry, 2000, 13, 333-338.	6.3	6
455	Therapeutic advances: Paroxetine for the treatment of social anxiety disorder. , 2000, 11, 99-104.		17
456	Quality of Life in Obsessive-Compulsive Disorder. CNS Spectrums, 2000, 5, 37-39.	1.2	20
457	Validation of the Spanish Version of the Changes in Sexual Functioning Questionnaire (CSFQ). Journal of Sex and Marital Therapy, 2000, 26, 119-131.	1.5	33
458	The importance of psychosocial interventions and patient involvement in the treatment of schizophrenia. International Journal of Psychiatry in Clinical Practice, 2000, 4, 35-51.	2.4	16
459	Sexual dysfunction in depressed patients undergoing treatment with antidepressants. International Journal of Psychiatry in Clinical Practice, 2000, 4, 311-317.	2.4	7
460	A European perspective on social anxiety disorder. European Psychiatry, 2000, 15, 5-16.	0.2	95
461	P01.163 For how long can be expected a sustained improvement in schizophrenic patients treated with antipyschotics? A clinical experience with risperidone. European Psychiatry, 2000, 15, 363s-364s.	0.2	0
462	P02.320 Safety and effectiveness of olanzapine versus typical antipsychotic drugs in the treatment of inpatients with schizophrenia (Europa study). European Psychiatry, 2000, 15, 409s-409s.	0.2	2
463	Paroxetine in social phobia/social anxiety disorder. British Journal of Psychiatry, 1999, 175, 120-126.	2.8	216
464	Quality of Life Assessment in Schizophrenia. , 1999, , 239-248.		2
465	Quality of life in schizophrenia: Long-term follow-up in 362 chronic Spanish schizophrenic outpatients undergoing risperidone maintenance treatment. European Psychiatry, 1998, 13, 158-163.	0.2	30
466	Quality of Life in Schizophrenia. European Psychiatry, 1997, 12, 116s-116s.	0.2	10
467	Searching for a predictive peripherical biological model in parasuicidal behaviour. European Psychiatry, 1997, 12, 75-81.	0.2	7
468	Brain glucose metabolism in borderline personality disorder. Journal of Psychiatric Research, 1997, 31, 531-541.	3.1	157

#	Article	IF	CITATIONS
469	Trends in suicide in the elderly in Asturias (Spain). European Psychiatry, 1995, 10, 339-344.	0.2	2
470	Synergistic effects of childhood adversity and polygenic risk in first-episode psychosis: the EU-GEI study. Psychological Medicine, 0, , 1-9.	4.5	10